Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | +48.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.13 | N/A | +48.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management remains focused on long-term goals while acknowledging short-term hurdles. They are optimistic about upcoming product launches.
Management highlighted ongoing investments in product development.
They expressed confidence in future growth despite current challenges.
Veracyte's earnings report shows a significant EPS surprise, indicating better-than-expected performance on that front. However, the lack of revenue data and no guidance updates may have contributed to the slight decline in stock price. Investors will be looking for more clarity in future reports to gauge the company's growth trajectory.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SOUTHERN COPPER CORP
Jul 26, 2021